Average Co-Inventor Count = 4.33
ph-index = 24
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Regeneron Pharmaceuticals, Inc. (325 from 1,333 patents)
2. Yale University (21 from 1,321 patents)
3. Institute for Research in Biomedicine (irb) (20 from 20 patents)
4. Regeneran Pharmaceuticals, Inc. (12 from 49 patents)
5. Cadus Technologies, Inc. (5 from 16 patents)
6. Cadus Pharmaceutical Corp. (3 from 9 patents)
7. Other (2 from 832,448 patents)
8. Duke University (1 from 2,001 patents)
9. Institute for Research in Biomedicine (1 from 56 patents)
347 patents:
1. 12448435 - Anti-TMPRSS6 antibodies and uses thereof
2. 12441797 - Anti-FC ϵ-R1 α (FCϵR1α) antibodies, bispecific antigen-binding molecules that bind FCϵR1α and CD3, and uses thereof
3. 12441800 - Bispecific anti-PSMA x anti-CD28 antibodies and uses thereof
4. 12441784 - Human antibodies to artemin and methods of use thereof
5. 12433266 - Humanized light chain mice
6. 12433265 - Non-human animals having a humanized a proliferation-inducing ligand gene
7. 12433264 - Non-human animals having an engineered immunoglobulin lambda light chain locus
8. 12419282 - Non-human animals expressing humanized CD3 complex
9. 12415856 - EGFR x CD28 multispecific antibodies
10. 12414551 - Genetically modified major histocompatibility complex mice
11. 12404505 - Delivery of a gene-editing system with a single retroviral particle and methods of generation and use
12. 12402611 - Genetically modified mice and engraftment
13. 12391753 - Antigen binding molecule formats
14. 12389888 - Mice expressing a limited immunoglobulin light chain repertoire
15. 12376573 - Genetically modified mice comprising humanized cellular immune system components with improved diversity of TCRB repertoire